Bio Diagnostics Company Investment Opportunity in Phoenix, USA
Gene therapy and biomarker/diagnostic company focused on neurological conditions including; ALS, Parkinson's, Alzheimer's and TBI.
| Established | 1-5 year(s) |
| Employees | 2 - 5 |
| Legal Entity | C Corporation |
| Reported Sales | USD 150 thousand |
| Run Rate Sales | USD 150 thousand |
| EBITDA Margin | Nil |
| Industries | Bio Diagnostics |
| Locations | Phoenix |
| Local Time | 11:42 AM America / Phoenix |
| Listed By | Management Member |
| Status | Active |
Partial Stake Sale
USD
20 million
for
20.0%
stake
(Native Currency: USD 20,000,000)
Reason: Expansion into new lab space with equipment to begin testing in human gene therapy treatments.
Includes physical assets worth
USD
18 million
Interested to connect with advisors
Name, Phone, Email
Available after connect
Business Name
Available after connect
User Verification
Documents
Business Overview
- Business primarily focused on gene therapy and biomarker/diagnostic services, with a specific emphasis on neurological conditions such as ALS, Parkinson's, Alzheimer's, and TBI.
- Offers biomarker testing as a CRO for pharma and researchers. Additionally, it is involved in the development of Adeno-Associated Viruses (AAVs) for neurodegenerative disorders, with a particular focus on inflammation and targeting neurons and glial cells.
- Has patented and licensed technologies from premier research institutions.
- The company generates revenue on a per research project basis, with an average project duration of 3 months and an average value ranging from $8,000 to $25,000. It has successfully completed projects for 10 different research companies since its inception.
- The company is currently engaged in a gene therapy research project involving 2,600 samples.
- There are 2 permanent employees, additionally, we have a few temporary employees/interns as well.
- Offers biomarker testing as a CRO for pharma and researchers. Additionally, it is involved in the development of Adeno-Associated Viruses (AAVs) for neurodegenerative disorders, with a particular focus on inflammation and targeting neurons and glial cells.
- Has patented and licensed technologies from premier research institutions.
- The company generates revenue on a per research project basis, with an average project duration of 3 months and an average value ranging from $8,000 to $25,000. It has successfully completed projects for 10 different research companies since its inception.
- The company is currently engaged in a gene therapy research project involving 2,600 samples.
- There are 2 permanent employees, additionally, we have a few temporary employees/interns as well.
Products & Services Overview
Biomarker testing as a CRO for pharma and researchers and developing AAVs for neurodegenerative disorders with a focus on inflammation including targeting neurons and glial cells.
Assets Overview
Physical assets include lab equipment and furniture.
Facilities Overview
Currently operate out of a rented facility in a small hospital-owned CLIA lab in Thomas Road,Phoenix.
Capitalization Overview
Funded through CRO biomarker revenues and non-dilutive capital.Clean cap table with 7 individual shareholders with no shareholder owning more than 30%.
Recent Activity
-
Earlier than 15 daysIndividual Advisor, Mesquite, Financial Consultant connected with the Business
Tags:
Bio Diagnostics Company Investment Opportunity in Phoenix, United States
·Invest in Bio Diagnostics Company in Phoenix, United States
·Investment Opportunity in Phoenix, United States
·Bio Diagnostics Company Investment Opportunity
·Invest in Bio Diagnostics Company
·Invest in Phoenix, United States
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct. Note that SMERGERS is not liable for any loss, damage, costs, claims and expenses whatsoever arising from transacting with any other user from the website. The final responsibility of conducting a thorough due diligence and taking the transaction forward lies with the users. Please read best practices on SMERGERS.
Contact Business
3 Investors already contacted this Business.
Register below to connect now!
- Social
- Register
- Login
Who uses SMERGERS?
... and 122,500+ other businesses of all sizes.
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct.
You might also be interested in these businesses